https://www.selleckchem.com/products/ipi-549.html
Treatment persistence was high, as 49% of patients remained with mirabegron at 10-12 months. Adverse events were consistent with previous safety profile results of mirabegron, and no unexpected safety issues were observed. CONCLUSIONS Spanish patients treated with mirabegron in real clinical practice reported improvements in HRQoL, with a good tolerability and persistence to treatment. INTRODUCTION Urology is a specialty of medium risk of claim. Receiving a claim for medical professional liability is a stressful experience with signific
Gefällt mir
Kommentar
Teilen
